Search

Displaying results 1491 - 1500 of 8696 in total
  1. Target

    Nociceptin receptor

    go.drugbank.com/bio_entities/BE0002378
    TargetHumans

    G protein-coupled opioid receptor that functions as a receptor for the endogenous neuropeptide nociceptin. … Arrestins modulate signaling via G proteins and mediate the activation of alternative signaling pathways that lead to the activation of MAP kinases.

    Polypeptides: Nociceptin receptorSynonyms: Orphanin FQ receptor, Kappa-type 3 opioid receptor
  2. Target

    Thrombopoietin receptor

    go.drugbank.com/bio_entities/BE0003440
    TargetHumans

    Receptor for thrombopoietin that regulates hematopoietic stem cell renewal, megakaryocyte differentiation, and platelet formation. … Upon activation by THPO, induces rapid tyrosine phosphorylation and activation of JAK2, providing docking sites for many signaling proteins such as STAT5, SHIP/INPP5D, GRB2, SOS1 and PI3K (PubMed:15899890

    Polypeptides: Thrombopoietin receptorFunction: thrombopoietin receptor activity
  3. Target

    Poliovirus receptor

    go.drugbank.com/bio_entities/BE0004247
    TargetHumans

    May also promote NK cell-target cell modular exchange, and PVR transfer to the NK cell. … This may trigger adhesion and secretion of lytic granules and IFN-gamma and activate cytotoxicity of activated NK cells.

    Polypeptides: Poliovirus receptor
  4. Target

    NMDA receptor

    go.drugbank.com/bio_entities/BE0004956
    TargetHumans

    By competing with GIT1 interaction with ARHGEF7/beta-PIX, may reduce GIT1/ARHGEF7-regulated local activation of RAC1, hence affecting signaling and limiting the maturation and growth of inactive synapses … Forms excitatory glycinergic receptor complexes with GluN1 alone which are activated by glycine binding to the GluN1 and GluN3 subunits.

    Polypeptides: Glutamate receptor ionotropic, NMDA 1, Glutamate receptor ionotropic, NMDA 2ASynonyms: Glutamate [NMDA] receptor subunit zeta-1, N-methyl-D-aspartate receptor subunit NR1
  5. Target

    Somatostatin receptor

    go.drugbank.com/bio_entities/BE0010008
    TargetHumans

  6. Target

    Fibronectin receptor

    go.drugbank.com/bio_entities/BE0010279
    TargetHumans

    Integrin alpha-3/beta-1 is a receptor for epiligrin, thrombospondin and CSPG4. Alpha-3/beta-1 may mediate with LGALS3 the stimulation by CSPG4 of endothelial cells migration. … ITGA9:ITGB1 may play a crucial role in SVEP1/polydom-mediated myoblast cell adhesion (By similarity).

    Synonyms: Fibronectin receptor subunit alpha, Fibronectin receptor subunit beta
  7. Target

    Adiponectin receptor

    go.drugbank.com/bio_entities/BE0010287
    TargetHumans

    Receptor for ADIPOQ, an essential hormone secreted by adipocytes that regulates glucose and lipid metabolism (PubMed:12802337, PubMed:25855295). … Receptor for ADIPOQ, an essential hormone secreted by adipocytes that regulates glucose and lipid metabolism (PubMed:12802337, PubMed:25855295). Required for normal body fat and glucose homeostasis.

    Polypeptides: Adiponectin receptor protein 1, Adiponectin receptor protein 2Synonyms: Progestin and adipoQ receptor family member 1, Progestin and adipoQ receptor family member I
  8. Drug

    Sulfadoxine

    go.drugbank.com/drugs/DB01299
    ApprovedInvestigationalWithdrawn

    A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.

  9. Drug

    Inavolisib

    go.drugbank.com/drugs/DB15275
    ApprovedInvestigational

    Inavolisib is an inhibitor of PI3Kα that was approved by the FDA in October 2024 for the treatment of certain patients with advanced breast cancers. … [L51748,L51738] In February 2025, it was approved by Health Canada for the same indication. [L52605]

    Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 Enzyme Inducers
  10. Drug

    Uridine triacetate

    go.drugbank.com/drugs/DB09144
    Approved

    Like many other neoplastic agents, these side effects limit the doses of 5-FU that can be administered, which also affects the efficacy for treatment. … By pre-administering with uridine (as the prodrug uridine triacetate), higher doses of 5-FU can be given allowing for improved efficacy and a reduction in toxic side effects [A18578].